glp-1 agonist in esrd Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists GLP-1 agonists in the treatment
Description
Tanaka M, Matsuo Y, Yamakage H, Masuda S, Terada Y, Muranaka K, et al
Advertising on our site helps support our mission
Examples of these advancements include the investigation and development of glucagonlike peptide 1 (GLP1) agonists and dipeptidyl peptidase4 inhibitors (DPP4is) [10, 11]
For the groups randomized to placebo, 1.2 mg of pemvidutide, 1.8 mg, and 2.4 mg,, week-24 absolute reduction in liver volume, which is linked to overall mortality, was 3.3%, 12.6%, 19.1%, and 18.0%
Nigel H
These effects are currently being evaluated in clinical trials
